Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study
Ashley Alex, Caila B. Vaughn, Melissa Rayhill
Headache The Journal of Head and Face Pain (2020) Vol. 60, Iss. 10, pp. 2454-2462
Closed Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
Lucas Hendrik Overeem, Andreas Peikert, Maxi Dana Hofacker, et al.
Cephalalgia (2021) Vol. 42, Iss. 4-5, pp. 291-301
Open Access | Times Cited: 93
Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide’s Motor-Stimulating and Prosecretory Function in the Intestine
Peter Holzer, Ulrike Holzer‐Petsche
Frontiers in Physiology (2022) Vol. 12
Open Access | Times Cited: 55
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 38
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
Albert Muñoz‐Vendrell, Sergio Campoy, Edoardo Caronna, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 28
Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
Wenfang Sun, Yali Li, Binbin Xia, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 11
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 33
Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers
Mamoru Shibata, Kazuki Fujita, Eri Hoshino, et al.
BMC Neurology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
Tsubasa Takizawa, Seiya Ohtani, Narumi Watanabe, et al.
BMC Neurology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 27
A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond
Michael L. Garelja, Debbie L. Hay
Headache The Journal of Head and Face Pain (2022) Vol. 62, Iss. 9, pp. 1093-1104
Open Access | Times Cited: 23
Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Cephalalgia (2023) Vol. 43, Iss. 5, pp. 033310242311776-033310242311776
Open Access | Times Cited: 15
Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study
Reem Suliman, Vanessa Santos, Ibrahim Al Qaisi, et al.
Neurology International (2024) Vol. 16, Iss. 1, pp. 274-288
Open Access | Times Cited: 5
A head‐to‐head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene–related peptide for chronic and episodic migraine
Francesco Saccà, Simone Braca, Mattia Sansone, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 6, pp. 788-794
Open Access | Times Cited: 11
Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study
David W. Dodick, Stewart J. Tepper, Jessica Ailani, et al.
Headache The Journal of Head and Face Pain (2025)
Open Access
Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
Jean Schoenen, Grégory Timmermans, Romain Nonis, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 26
Alopecia signals associated with calcitonin gene‐related peptide inhibitors in the treatment or prophylaxis of migraine: A pharmacovigilance study
Richard H. Woods
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2022) Vol. 42, Iss. 10, pp. 758-767
Closed Access | Times Cited: 18
A stated preference survey to explore patient preferences for novel preventive migraine treatments
Lena Hubig, Timothy R. Smith, Gin Nie Chua, et al.
Headache The Journal of Head and Face Pain (2022) Vol. 62, Iss. 9, pp. 1187-1197
Open Access | Times Cited: 17
Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene‐related peptide responsive receptors
Michael L. Garelja, Tyla I. Alexander, Amy Bennie, et al.
British Journal of Pharmacology (2023) Vol. 181, Iss. 1, pp. 142-161
Open Access | Times Cited: 9
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
Maurice T. Driessen, Joshua M. Cohen, Oscar Patterson‐Lomba, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Measuring interictal burden among people affected by migraine: a descriptive survey study
Lena Hubig, Timothy R. Smith, Emma Williams, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study
Adrián Viudez‐Martínez, Angela Pascual‐Carrasco, Isabel Beltrán‐Blasco, et al.
Journal of Clinical Pharmacy and Therapeutics (2022) Vol. 47, Iss. 6, pp. 814-823
Open Access | Times Cited: 12
Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine
Michelle Sojung Youn, Namoh Kim, Mi Ji Lee, et al.
Journal of Clinical Neurology (2024) Vol. 20, Iss. 3, pp. 300-300
Open Access | Times Cited: 2
A Review of Calcitonin Gene-Related Peptide and Its Implications for Vestibular Disorders
R L Baron, Kristen K. Steenerson
Current Treatment Options in Neurology (2024) Vol. 26, Iss. 6, pp. 203-228
Closed Access | Times Cited: 2
Comparative effectiveness and tolerability of calcitonin gene‐related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real‐world study in Taiwan
Yen‐Feng Wang, Fu‐Chi Yang, Lu‐An Chen, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 9
Open Access | Times Cited: 2
PEARL Study Protocol: a Real-World Study of Fremanezumab Effectiveness in Patients with Chronic or Episodic Migraine
Messoud Ashina, Faisal Mohammad Amin, Pinar Kokturk, et al.
Pain Management (2021) Vol. 11, Iss. 6, pp. 647-654
Open Access | Times Cited: 15
Combining two CGRP inhibitors to treat migraine
Lanfranco Pellesi
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 9, pp. 1135-1136
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top